Insights On Drug Discovery

  1. The Gateway Delivery To The Brain 1/30/2026

    Nose‑to‑brain delivery enables targeted neurological treatment by using direct neural pathways to boost precision and limit systemic exposure, with new formulations and devices driving rapid progress.

  2. Covalent Warhead Reactivity: A New Look At GSH Reactivity Assays 1/26/2026

    Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.

  3. Flow Chemistry For Contemporary Isotope Labeling 1/26/2026

    Gain insight into how late‑stage exchange and flow‑based methods enable efficient access to labeled molecules for pharmaceuticals, mechanistic studies, and analytical applications.

  4. Optimizing Lentiviral Producer Cell Line Yield 12/15/2025

    Producer cell lines boost lentiviral manufacturing efficiency via high-density culture, multiple harvests, and additive optimization for scalable production.

  5. Patient-Centric Formulations In Pediatric Adherence 11/13/2025

    Improving pediatric adherence requires age-appropriate formulations, taste-masking, and swallowability strategies. Regulatory, clinical, and technological insights help overcome barriers and support safer, more effective therapies for children across developmental stages.

  6. Scientific Poster: Driving High-Titer Productivity And Faster Timelines 11/13/2025

    Accelerated cell line development delivers high-titer biologics in weeks, supporting diverse modalities with robust analytics, scalable productivity, and proven stability across 60+ generations.

  7. Top 5 Cell Line Development Challenges (And How To Avoid Them) 11/6/2025

    The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

  8. Optimize Your CLD With Innovative And Flexible Transposase Technology 11/6/2025

    To ensure speed and stability in the manufacture of your complex biologic — mAbs, antibodies, fusion proteins, and/or antibody drug conjugates — prioritize a high-performance CLD workflow.

  9. Achieve Speed, Stability, And Compliance In Cell Line Development 11/6/2025

    Partnering with a CDMO that demonstrates innovative and commercially validated cell line development capabilities is essential to protecting your market position and securing investor support.

  10. Smart Input Selection And Process Refinement For iPBMCs 11/5/2025

    Improved iPBMC manufacturing boosts TIL therapy reliability, safety, and affordability through donor screening, process refinements, and performance-based cell selection.